Trial Profile
A Randomized, Double-blind, Multicenter, 2-period Single-dose Cross-over Study to Assess the Early Bronchodilation of Glycopyrronium Bromide (44 µg o.d.) Compared to Tiotropium (18 µg. o.d.) in Patients With Moderate to Severe COPD (FAST Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jul 2020
Price :
$35
*
At a glance
- Drugs Glycopyrrolate (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms FAST
- Sponsors Novartis; Novartis Pharma
- 22 May 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 27 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Jan 2014 according to ClinicalTrials.gov record.
- 19 Aug 2013 New trial record